A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1

• Published in: International journal of clinical oncology 2007-08, Vol.12 (4), p.295-299
• Main Authors: Nakamura, Rieko, Saikawa, Yoshiro, Kumagai, Koushi, Kiyota, Tsuyoshi, Ohashi, Masaki, Yoshida, Masashi, Kubota, Tetsuro, Kumai, Koichiro, Kitajima, Masaki
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer; Chemotherapy; Cisplatin - administration & dosage; Clinical outcomes; Combined Modality Therapy; Drug Combinations; Humans; Liver; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Liver Neoplasms - secondary; Male; Middle Aged; Oxonic Acid - administration & dosage; Oxonic Acid - therapeutic use; Radiation therapy; Stomach; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Stomach Neoplasms - surgery; Surgery; Taxoids - administration & dosage; Tegafur - administration & dosage; Tegafur - therapeutic use
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-006-0648-4

We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1. The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19. This chemotherapy resulted in significant reduction of the liver and gastric tumors. After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT). With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+alpha lymph node dissection, and partial resection of liver S4. After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis. Additionally, a third regimen with irinotecan and S-1 was given. At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.